Mirna Therapeutics (MIRN): Cutting PT After The MRX34 Program Was Terminated - Leerink
Tweet Send to a Friend
Leerink Partners analyst, Michael Schmidt, reiterated his Market Perform rating on shares of Mirna Therapeutics. (NASDAQ: MIRN) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE